Yu Sunakawa, MD, PhD, St. Marianna University School of Medicine, Kawasaki, Japan, talks on the findings of the DEEPER trial, evaluating the efficacy and safety of bevacizumab versus cetuximab in combination with FOLFOXIRI in previously untreated metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors. Modified FOLFOXIRI plus cetuximab has been shown to be significantly superior to the modified FOLFOXIRI plus bevacizumab in terms of depth of response in the treatment of first-line (1L) mCRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
